Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug;39(4):303-7.
doi: 10.1007/s00240-010-0347-5. Epub 2010 Dec 17.

Nephrolithiasis in topiramate users

Naim M Maalouf  1 , Joshua P Langston, Paul C Van Ness, Orson W Moe, Khashayar Sakhaee
Affiliations

Nephrolithiasis in topiramate users

Naim M Maalouf et al. Urol Res. 2011 Aug.

Abstract

Topiramate is a neuromodulatory agent increasingly prescribed for a number of neurological and non-neurological indications. Topiramate-treated patients are at risk for nephrolithiasis due to hypocitraturia and high urine pH. However, the prevalence of symptomatic stone disease in TPM users is generally perceived to be low. This study was undertaken to assess in topiramate-treated patients the prevalence of symptomatic nephrolithiasis (by history) and of asymptomatic nephrolithiasis by computed tomography (CT) scan. Topiramate users were identified from a database of patients with neurological disorders at a single university hospital. Among 75 topiramate-treated adult patients with a median daily dose of 300 mg and median treatment duration of 48 months, the prevalence of symptomatic nephrolithiasis was 10.7%. In a subset of topiramate-treated patients and no history of symptomatic stone disease, the prevalence of asymptomatic nephrolithiasis detected by CT scan was 20%. The prevalence of symptomatic nephrolithiasis with long-term topiramate use is higher than reported in short-term studies. Furthermore, clinical prevalence is underestimated due to asymptomatic nephrolithiasis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cohort information
Fig. 2
Fig. 2
Asymptomatic nephrolithiasis in a patient on long-term topiramate
See this image and copyright information in PMC

References

    1. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G Topiramate YP Study Group. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology. 1999;52(7):1338–1344. - PubMed
    1. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, Pledger G Topiramate YTC Study Group. A randomized, placebo-controlled study of topiramate in primary generalized tonic–clonic seizures. Neurology. 1999;52(7):1330–1337. - PubMed
    1. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwabe S, Jacobs D. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965–973. - PubMed
    1. D’Amico D, Grazzi L, Usai S, Moschiano F, Bussone G. Topiramate in migraine prophylaxis. Neurol Sci. 2005;26(Suppl 2):s130–s133. - PubMed
    1. Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf. 2007;6(5):547–557. - PubMed

Publication types